A Phase II Study of Doxorubicin/Paclitaxel Plus G-CSF for Metastatic Breast Cancer
ByGilberto Schwartsmann, MD, PhD,Denis Ricardo Mans, PhD,Carlos Henrique Menke, MD,Nilton Xavier, MD,Maira Caleffi, MD, PhD,Ferreira Filho, MD, PhD,Hugo Schunemann, MD,Luciane Kalakun, RN,Richard Koya, MD,Paula Pohlman, MD,Luiz Fernando Venegas, MD
Published: | Updated:
This phase II trial was conducted to evaluate the percentage of objective responses and the toxicity profile of combination doxorubicin (Adriamycin) and paclitaxel (Taxol) with granulocyte colony-stimulating factor as first-line